Estimating the economic benefits of positive shifts in fibromyalgia severity: an exploratory analysis based on modeling of clinical trial data of pregabalin

References

• Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72
   PubMed Web of Science ®Google Scholar
• Bennett RM, Jones J, Turk DC, et al. An internet survey of 2596 people with fibromyalgia. BMC Musculoskelet Disord 2007;8:27
   PubMed Web of Science ®Google Scholar
• Arnold LM, Crofford LJ, Mease PJ, et al. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns 2008;73:114-20
   PubMed Web of Science ®Google Scholar
• Silverman S, Sadosky A, Evans C, et al. Toward characterization and definition of fibromyalgia severity. BMC Musculoskelet Disord 2010;11:66
   PubMed Web of Science ®Google Scholar
• Wolfe F, Clauw DJ, Fitzcharles M-A, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 2010;62:600-10
   PubMed Web of Science ®Google Scholar
• Mease P, Arnold LM, Choy EH, et al. Fibromyalgia Syndrome Module at OMERACT 9: Domain Construct. J Rheumatol 2009;36:2318-29
   PubMed Web of Science ®Google Scholar
• Hughes G, Martinez C, Myon E, et al. The impact of a diagnosis of fibromyalgia on health care resource use by primary care patients in the UK. An observational study based on clinical practice. Arthritis Rheum 2006;54:177-83
   PubMed Web of Science ®Google Scholar
• Berger A, Dukes E, Martin S, et al. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract 2007;61:1498-508
   PubMed Web of Science ®Google Scholar
• White LA, Birnbaum HG, Kaltenboeck A, et al. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med 2008;50:13-24
   PubMed Web of Science ®Google Scholar
• Berger A, Sadosky A, Dukes E, et al. Characteristics and patterns of healthcare utilization of patients with fibromyalgia in general practitioner settings in Germany. Curr Med Res Opin 2008;24:2489-99
   PubMed Web of Science ®Google Scholar
• Sicras-Mainar A, Rejas J, Navarro R, et al. Treating patients with fibromyalgia in primary care settings under routine medical practice: a claim database cost and burden of illness study. Arthritis Res Ther 2009;11:R54
   PubMed Web of Science ®Google Scholar
• Robinson RL, Birnbaum HG, Morley MA, et al. Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol 2003;30:1318-25
   PubMed Web of Science ®Google Scholar
• Kleinman N, Harnett J, Melkonian A, et al. Burden of fibromyalgia and comparisons with osteoarthritis in the workforce. J Occup Environ Med 2009;51:1384-93
   PubMed Web of Science ®Google Scholar
• Chandran A, Schaefer C, Ryan K, et al. The comparative economic burden of mild, moderate, and severe fibromyalgia: results from a retrospective chart review and a cross-sectional survey of working-age U.S. adults. J Manag Care Pharm 2012;18:415-26
   PubMed Web of Science ®Google Scholar
• Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991;18:728-33
   PubMed Web of Science ®Google Scholar
• Field MJ, Cox PJ, Stott E, et al. Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci USA 2006;103:17537-42
   PubMed Web of Science ®Google Scholar
• Errante LD, Petroff OA. Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure 2003;12:300-6
   PubMed Web of Science ®Google Scholar
• Cunningham MO, Woodhall GL, Thompson SE, et al. Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. Eur J Neurosci 2004;20:1566-76
   PubMed Web of Science ®Google Scholar
• Maneuf YP, Hughes J, McKnight AT. Gabapentin inhibits the substance P-facilitated K(+)-evoked release of [(3)H]glutamate from rat caudial trigeminal nucleus slices. Pain 2001;93:191-6
   PubMed Web of Science ®Google Scholar
• Pfizer Inc. Lyrica® [pregabalin] capsules prescribing information. New York, NY: Pfizer Inc, 2012
   Google Scholar
• Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008;35:502-14
   PubMed Web of Science ®Google Scholar
• Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blind, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008;9:792-805
   PubMed Web of Science ®Google Scholar
• Pauer L, Winkelmann A, Arsenault P, et al. An international, randomized, double-blind, placebo-controlled, phase III Trial of pregabalin monotherapy in treatment of patients with fibromyalgia. J Rheumatol 2011;38:2643-52
   PubMed Web of Science ®Google Scholar
• Bennett RM, Bushmakin AG, Cappelleri JC, et al. Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol 2009;36:1304-11
   PubMed Web of Science ®Google Scholar
• Arnold LM, Emir B, Murphy TK, et al. Safety profile and tolerability of up to 1 year of pregabalin treatment in 3 open-label extension studies in patients with fibromyalgia. Clin Ther 2012;34:1092-102
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid. www.cms.gov. A federal government website managed by the Centers for Medicare & Medicaid Services, 7500 Security Boulevard, Baltimore, MD, 21244. Accessed November 18, 2011
   Google Scholar
• Tzellos TG, Toulis KA, Goulis DG, et al. Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis. J Clin Pharm Ther 2010;35:639-56
   PubMed Web of Science ®Google Scholar
• Straube S, Derry S, Moore RA, et al. Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. Rheumatology (Oxford) 2010;49:706-15
   PubMed Web of Science ®Google Scholar
• Lachaine J, Beauchemin C, Landry PA. Clinical and economic characteristics of patients with fibromyalgia syndrome. Clin J Pain 2010;26:284-90
   PubMed Web of Science ®Google Scholar
• Palacio A, Uribe CL, Li H, et al. Financial and clinical characteristics of fibromyalgia: a case-control comparison. Am J Manag Care 2010;16(Suppl):S118-S25
   PubMedGoogle Scholar
• Schaefer C, Chandran A, Hufstader M, et al. The comparative burden of mild, moderate and severe fibromyalgia: results from a cross-sectional survey in the United States. Health Qual Life Outcomes 2011;9:71
   PubMed Web of Science ®Google Scholar
• Kleinman NL, Sanchez RJ, Lynch WD, et al. Health outcomes and costs among employees with fibromyalgia treated with pregabalin vs. standard of care. Pain Pract 2011;11:540-51
   PubMedGoogle Scholar
• Burke JP, Sanchez R, Joshi AV, et al. Health care costs in patients with fibromyalgia on pregabalin vs. duloxetine. Pain Pract 2011;12:14-22
   PubMedGoogle Scholar
• Harnett J, Margolis J, Cao Z, et al. Real-world evaluation of health-care resource utilization and costs in employees with fibromyalgia treated with pregabalin or duloxetine. Pain Pract 2011;11:217-29
   PubMed Web of Science ®Google Scholar
• Gore M, Tai K-S, Chandran A, et al. Clinical comorbidities, treatment patterns, and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual care. J Med Econ 2012;15:19-31
   PubMedGoogle Scholar
• Zhao Y, Sun P, Watson P, et al. Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia. Pain Pract 2011;11:204-16
   PubMed Web of Science ®Google Scholar